Chemokines and cardiovascular risk

Area of Science:

• Cardiovascular Science
• Inflammation Biology
• Biomarker Discovery

Background:

• Inflammation is crucial in the development of atherosclerosis.
• Chemokines are implicated in the pathogenesis of atherosclerosis and are potential therapeutic targets.
• Ideal biomarkers for cardiovascular disease require stable levels and protein stability.

Purpose of the Study:

• To evaluate the suitability of plasma inflammatory markers, specifically chemokines, for diagnosing and predicting atherosclerotic disorders.
• To assess the potential of chemokines as clinical biomarkers for cardiovascular disease risk.

Main Methods:

• Review of existing studies on plasma chemokine levels and their association with atherosclerosis and cardiac events.
• Analysis of criteria for ideal biomarkers, including stability and reflection of upstream inflammatory activity.

Main Results:

• Some studies suggest certain chemokines (e.g., CXCL8, CCL2) may predict future cardiac events.
• The role of chemokines as clinical biomarkers remains unclear.
• Their ability to predict subclinical atherosclerosis has been disappointing.

Conclusions:

• Chemokines' role in atherosclerosis does not automatically qualify them as reliable risk prediction biomarkers.
• Further large-scale prospective studies are necessary to confirm their utility.
• Combined measurements of multiple chemokines might serve as a future "disease signature" for assessing atherosclerotic disease presence.